SLC5A2 and type 2 diabetes mellitus: Current guidelines recommend the early use of SGLT2 inhibitors in T2DM treatment, particularly for patients with established or high risk of atherosclerotic cardiovascular disease (ASCVD), HF, or CKD [46,47,48].